§285c–9 — Title 42 The Public Health and Welfare | U.S. Code

§285c–9 Juvenile diabetes

Title 42 › Chapter CHAPTER 6A— - PUBLIC HEALTH SERVICE › Subchapter SUBCHAPTER III— - NATIONAL RESEARCH INSTITUTES › Part Part C— - Specific Provisions Respecting National Research Institutes › Subpart subpart 3— - national institute of diabetes and digestive and kidney diseases › § 285c–9

Last updated Apr 6, 2026|Official source

Summary

The Director of the Institute must run or pay for long-term studies that follow people who have, or are at risk for, type 1 (juvenile) diabetes for 10 years or more. Those studies must look into what causes the disease, how it behaves over time, and the health problems it leads to. The Secretary, through the NIH Director, must back regional clinical research centers that work on preventing, finding, treating, and curing juvenile diabetes. The Secretary must also lead a national prevention effort, using the right agencies, that increases research and develops prevention plans (including study of vaccines) and can test those plans in large clinical trials of children and young adults.

Title 42, §285c–9

The Public Health and Welfare — Source: USLM XML via OLRC

(a)The Director of the Institute shall conduct or support long-term epidemiology studies in which individuals with or at risk for type 1, or juvenile, diabetes are followed for 10 years or more. Such studies shall investigate the causes and characteristics of the disease and its complications.

(b)The Secretary, acting through the Director of the National Institutes of Health, shall support regional clinical research centers for the prevention, detection, treatment, and cure of juvenile diabetes.

(c)The Secretary, acting through the appropriate agencies, shall provide for a national effort to prevent type 1 diabetes. Such effort shall provide for a combination of increased efforts in research and development of prevention strategies, including consideration of vaccine development, coupled with appropriate ability to test the effectiveness of such strategies in large clinical trials of children and young adults.

Notes & Related Subsidiaries

Editorial Notes

Amendments

2007—Subsec. (d). Pub. L. 109–482 struck out heading and text of subsec. (d). Text read as follows: “For the purpose of carrying out this section, there are authorized to be appropriated such sums as may be necessary for each of the fiscal years 2001 through 2005.”

Statutory Notes and Related Subsidiaries

Effective Date

of 2007 AmendmentAmendment by Pub. L. 109–482 applicable only with respect to amounts appropriated for fiscal year 2007 or subsequent fiscal years, see section 109 of Pub. L. 109–482, set out as a note under section 281 of this title.